BRAF and central nervous system cancer: Particularly in younger glioma patients as well as in patients with an epithelioid glioblastoma, screening for a <i>V600E BRAF</i> mutation is promising since, in these cases, targeted therapy with <i>BRAF</i> inhibitors seems to be a useful salvage treatment option.